Paul Ruff to Biomarkers, Tumor
This is a "connection" page, showing publications Paul Ruff has written about Biomarkers, Tumor.
Connection Strength
0,393
-
Computational Analysis of miRNA and their Gene Targets Significantly Involved in Colorectal Cancer Progression. Microrna. 2019; 8(1):68-75.
Score: 0,158
-
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010 Nov 01; 28(31):4697-705.
Score: 0,089
-
PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients-a South African cohort study. Breast Cancer Res Treat. 2023 Aug; 200(3):337-346.
Score: 0,054
-
Discordance between PAM50 intrinsic subtyping and immunohistochemistry in South African women with breast cancer. Breast Cancer Res Treat. 2023 May; 199(1):1-12.
Score: 0,053
-
Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study. Clin Cancer Res. 2019 02 15; 25(4):1216-1225.
Score: 0,039